Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Endometrial cancer and hormone-replacement therapy in the Million Women Study.

Beral V, Bull D, Reeves G; Million Women Study Collaborators.

Lancet. 2005 Apr 30-May 6;365(9470):1543-51.

PMID:
15866308
2.

Breast cancer and hormone-replacement therapy in the Million Women Study.

Beral V; Million Women Study Collaborators.

Lancet. 2003 Aug 9;362(9382):419-27. Erratum in: Lancet. 2003 Oct 4;362(9390):1160.

PMID:
12927427
3.

Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women.

Beresford SA, Weiss NS, Voigt LF, McKnight B.

Lancet. 1997 Feb 15;349(9050):458-61.

PMID:
9040575
4.

Use of HRT and the subsequent risk of cancer.

Beral V, Banks E, Reeves G, Appleby P.

J Epidemiol Biostat. 1999;4(3):191-210; discussion 210-5. Review.

PMID:
10695959
5.

Hormone replacement therapy and false positive recall in the Million Women Study: patterns of use, hormonal constituents and consistency of effect.

Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J.

Breast Cancer Res. 2006;8(1):R8. Epub 2005 Dec 23.

6.

The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy.

Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC, Bragg AJ.

BJOG. 2000 Nov;107(11):1392-400. Erratum in: BJOG 2001 Mar;108(3):335.

7.

[Indications for hormone replacement therapy].

Birkhäuser MH.

Ther Umsch. 2000 Oct;57(10):635-42. Review. German.

PMID:
11081375
8.

Cancer issues.

Marsden J, Sturdee D.

Best Pract Res Clin Obstet Gynaecol. 2009 Feb;23(1):87-107. doi: 10.1016/j.bpobgyn.2008.10.005. Epub 2008 Nov 25.

PMID:
19036643
9.

Continuous low-dose combined hormone replacement therapy and the risk of endometrial cancer.

Comerci JT Jr, Fields AL, Runowicz CD, Goldberg GL.

Gynecol Oncol. 1997 Mar;64(3):425-30.

PMID:
9062144
10.

Hormone replacement therapy and cancer.

[No authors listed]

Gynecol Endocrinol. 2001 Dec;15(6):453-65. Review.

PMID:
11826770
11.

Continuous combined hormone replacement therapy compared with tibolone.

Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T.

Obstet Gynecol. 1999 Feb;93(2):258-64.

PMID:
9932566
13.

Endometrial safety and bleeding with HRT: what's new?

Sturdee DW.

Climacteric. 2007 Oct;10 Suppl 2:66-70. Review.

PMID:
17882676
14.

Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.

de Vries CS, Bromley SE, Thomas H, Farmer RD.

Drug Saf. 2005;28(3):241-9.

PMID:
15733028
15.

Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.

Reeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study Collaborators.

Lancet Oncol. 2006 Nov;7(11):910-8.

PMID:
17081916
16.

Effect of endogenous and exogenous hormones on breast cancer: epidemiology.

Vessey MP.

Verh Dtsch Ges Pathol. 1997;81:493-501. Review.

PMID:
9474890
17.

Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users.

Hänggi W, Bersinger N, Altermatt HJ, Birkhäuser MH.

Maturitas. 1997 Jun;27(2):133-43.

PMID:
9255748
18.

[Hormone replacement therapy and cancer].

Bjørge T, Tropé C.

Tidsskr Nor Laegeforen. 1997 Jun 10;117(15):2201-7. Review. Norwegian.

PMID:
9235712
19.

Ovarian cancer and hormone replacement therapy in the Million Women Study.

Beral V; Million Women Study Collaborators, Bull D, Green J, Reeves G.

Lancet. 2007 May 19;369(9574):1703-10.

PMID:
17512855
20.

Evidence from randomised trials on the long-term effects of hormone replacement therapy.

Beral V, Banks E, Reeves G.

Lancet. 2002 Sep 21;360(9337):942-4. Review.

PMID:
12354487
Items per page

Supplemental Content

Write to the Help Desk